Highlights Anteris Technologies Ltd

Equities

AVR

AU0000088841

Market Closed - Australian S.E. Other stock markets 11:40:14 09/05/2024 am IST			5-day change	1st Jan Change
21.07 ^AUD	-0.14%		-1.08%	+10.03%

18/04	Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31	MT
10/04	Anteris Technologies Raises AU$23 Million for DurAVR Study	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Anteris Technologies Posts AU$10.6 Million Cash, AU$20.2 Million Net Cash Outflows for Quarter Ended March 31	18/04	MT
Anteris Technologies Raises AU$23 Million for DurAVR Study	10/04	MT
Anteris Technologies Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Anteris Technologies Secures AU$1 Million Tax Rebate for 2022	13/23/13	MT
Anteris Technologies Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	25/23/25	CI
Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case	14/23/14	CI
Anteris Technologies Announces First Successful Implantation of Duravr? Thv in A Valve-In-Valve Procedure	31/23/31	CI
Anteris Technologies Secures US Patent for Transcatheter Heart Valve; Shares Rise 4%	17/23/17	MT
Anteris Technologies, v2vmedtech to Develop Heart Valve Repair Device	19/23/19	MT
Anteris Technologies Ltd acquired 30% stake in v2vmedtech, inc. for $0.37 million.	19/23/19	CI
Anteris Technologies Secures US Patent for Heart Valve Product; Shares Rise 3%	12/23/12	MT
US FDA Allows Manufacturing to Start at Anteris Technologies' Expanded Production Facility for DurAVR THV	27/23/27	MT
Anteris Technologies Ltd Announces FDA Allows Manufacturing to Begin At Expanded Facility	27/23/27	CI
Anteris Technologies Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	28/23/28	CI
Anteris Technologies Ltd Announces 12 Month Results for Anteris DurAVRTM Transcatheter Heart Valve Aortic Stenosis First in Human Study	16/23/16	CI
Anteris Technologies Secures US FDA Early Feasibility Study Approval for Heart Valve Device System	28/22/28	MT
Anteris Technologies Ltd Announces Fda Approves Early Feasibility Study for DurAVR THV System	28/22/28	CI
Anteris Technologies Ltd Announces Formal Results of A Comparative Study to Investigate Aortic Flow Physiology by Cardiac MRI in Five Patients Who Received A DurAVR Transcatheter Aortic Valve (First- In-Human)	28/22/28	CI
Anteris Technologies Ltd Presents "DurAVR transcatheter aortic valve first-in- human study: impact of novel leaflet design" at the annual PCR London Valves 2022, 27-29 November 2022	28/22/28	CI
Anteris Technologies Ltd Overnight Presents 30-Day Clinical Data for Full Cohort of 13 Patients Implanted with DurAVR THV During Its First-In-Human Trial	19/22/19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Anteris Technologies Ltd

Equities

AVR

AU0000088841

Highlights

Filters